vendredi 13 septembre 2019

Onco Actu du 13 septembre 2019


1. BIOLOGIE



Research Clears Up Mystery About Most Common Cancer Gene [Dana-Farber Cancer Institute]










How the body’s nerves become accomplices in the spread of cancer [Science]











3. PRÉVENTION



Cheap fags and booze: why now, more than ever, we need a whole government approach to health [BMJ]











3.1 PRÉVENTION - TABAC



Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows [NCI]











3.1.1 PRÉVENTION - TABAC - E-CIGS



A Ban on Flavored E-Cigarettes Would Sharply Cut Sales [NY Times]










U.S. cuts vaping-related illness total under refined case definition [Reuters]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Drug companies pay for exclusive access to UK genetic data [Biopharma Dive]











5. TRAITEMENTS



Infant with Deadly Leukemia Saved by Drug for Adult Liver Cancer [UCSF]










Patients With Metastatic Colorectal Cancer Harboring Certain BRAF Mutations May Respond to Anti-EGFR Therapy [AACR]











Carcinogens Have Infiltrated the Generic Drug Supply in the U.S. [Bloomberg]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Cancer Drugs in Development May Be Targeting Wrong Proteins [The Scientist]











Your Cancer Targets May Not Be Real [In The Pipeline]











5.12 IMMUNOTHÉRAPIES



Antibiotics reduce survival rates in cancer patients taking immunotherapy [Imperial College London]










Antibiotic use before cancer treatment cuts survival time – study [The Guardian]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



University of Pennsylvania Announces Completion of Exclusive R&D Alliance With Novartis and Development of New Focused Relationship [Penn Medicine]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Tocagen Stock Tanks After Gene Therapy Drug for Brain Cancer Fails [Xconomy]











Tocagen fails brain cancer test, sets about 'operational review' as shares routed [Fierce Biotech]











In a 'make or break' moment, Tocagen falls short [Biopharma Dive]










Tocagen shares collapse as investigators read last rites for PhIII brain cancer study [EndPoints]











Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer [Tocagen]











Tocagen's brain cancer treatment fails late-stage study, shares crash [Reuters]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Roche's Tecentriq scores solo win in lung cancer. But can it challenge Merck's Keytruda? [Fierce Pharma]











Roche's Tecentriq excels in another lung cancer study [EndPoints]











5.2 PHARMA



Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints [Celgene]











Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer [Roche]











FDA slaps a hold on one of Amgen’s early-stage cancer drugs, raising cardiac tox concerns for a top prospect in the pipeline [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Cancer drugs among US goods spared from tariffs as China issues first exemptions in trade war [EndPoints]











6. LUTTE CONTRE LES CANCERS



After nearly dying five times, a young doctor learned to treat himself. Now he wants to help others with rare disease [STAT]










6.1 OBSERVATION



UK cancer survival rates are too low – our priorities are all wrong [The Guardian]










6.11 PATIENTS



Cancer patients use crowdfunding for medical bills, expenses [Reuters]











6.12 ETHIQUE



Cancer researchers’ failure to disclose industry payments damages patient trust — and care [STAT]











6.9 CONTROVERSES



MSK picks brain cancer expert Lisa DeAngelis as its next CMO — following José Baselga’s controversial exit [EndPoints]